GSK Company Research Report

Company Overview

• Name: GlaxoSmithKline plc (GSK)

• Mission of the Company: To unite science, technology, and talent to get ahead of disease together. GSK aims to impact the health of 2.5 billion people by the end of the decade.

• Founded: No information is available.

• Key People: GSK’s leadership includes a global leadership team responsible for the company's ambition, strategy, and culture. However, specific names are not disclosed.

• Headquarters: Registered office at 79 New Oxford Street, London, United Kingdom, WC1A 1DG.

• Number of Employees: Approximately 70,200 people globally.

• Revenue: Group turnover was £30.3 billion in 2023.

• What the Company is Known For: GSK is a leading biopharma company renowned for its innovation in vaccines and specialty medicines focused on infectious diseases, HIV, respiratory/immunology, and oncology.

Products

1. Vaccines

• High-Level Description: GSK has a diverse portfolio of over 20 marketed vaccines targeting infectious diseases at all life stages.

• Key Features:

• Protection against diseases such as RSV, meningitis, shingles, flu, and polio.

• Over 1.5 million doses delivered daily.

2. Specialty Medicines

• High-Level Description: These are medicines prescribed by specialist healthcare practitioners.

• Key Features:

• Focus includes HIV, respiratory diseases, immune-mediated conditions, and oncology.

• Many involve first or best-in-class treatments.

3. General Medicines

• High-Level Description: Prescribed primarily in primary care settings.

• Key Features:

• Includes inhaled medicines for asthma and COPD, antibiotics, and medicines for skin diseases.

• Over 150 primary care products supplied in 112 countries.

Recent Developments

• New Products Launched:

• Arexvy (RSV Vaccine): Approved for use in Japan to protect adults aged 50-59 at increased risk of severe RSV disease (22 November 2024).

• New Features/Enhancements:

• Linerixibat: Demonstrated positive results in Phase III trials for cholestatic pruritus in primary biliary cholangitis (19 November 2024).

• Blenrep: Showed overall survival benefits in DREAMM-7 Phase III trials for relapsed/refractory multiple myeloma (14 November 2024).

• New Partnerships:

• Collaboration with Cambridge University in kidney and respiratory diseases with an investment of more than £50 million (21 October 2024).

• Agreement with Chimagen Biosciences to expand the immunology pipeline in lupus treatment (29 October 2024).

• Strategic Advances:

• GSK's Menveo meningococcal vaccine received a positive opinion from the European CHMP for a new single-vial, fully liquid presentation (24 September 2024).

• Data showcasing 99% effectiveness of Apretude in real-world studies for long-acting HIV PrEP (16 October 2024).

• Litigation and Settlements:

• Resolved approximately 80,000 U.S. state court Zantac product liability cases for up to $2.2 billion (09 October 2024).

Conclusion

GSK continues to lead the global biopharmaceutical landscape with robust advancements in their vaccine and specialty medicines portfolio. With a strong emphasis on innovative treatments across core therapeutic areas and an unwavering commitment to strategic partnerships, the company is steadily advancing its mission to enhance global health outcomes.